Berry Consultants Releases FACTS 7 Clinical Trial Simulator
Berry Consultants, LLC announced today that FACTS 7 was released to existing users and is now available to all new clients. FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, flexible, and fastest simulation tool on the market for advanced clinical trial design. FACTS covers the whole spectrum of trial designs, from early development phase I trials, to innovative phase II trials, and efficient phase III designs. With the release of FACTS 7 and the new platform trial module, FACTS becomes the first commercially available and validated software for the design and simulation of adaptive platform trials.
The Berry Consultants team is the internationally renowned leader in the creation, design, and implementation of platform trials in many disease areas such as ALS, Breast Cancer, Alzheimer’s, Pancreatic Cancer, Glioblastoma Multiforme, Influenza, Pneumonia, and COVID-19, and is currently expanding platform trials into many more disease areas for sponsors. These platform trials are built with a master protocol to allow multiple therapies to be investigated in a single trial, being added continuously, all with shared infrastructure. In addition, a platform trial allows multiple arms to share a common control, share the common infrastructure of the trial, and it allows the better treatment of patients in the trial. The platform trial concept is a win-win for all stakeholders – smaller sample size, reduced patients on placebo, reduced costs, reduced timelines, and better inferences for regulators. Now with FACTS 7, this innovative approach of platform trials can be shared to commercial clients through licensing the FACTS software package.
Scott Berry, PhD, President and Senior Statistical Scientist at Berry Consultants, said, “This is an exciting day for our FACTS software and all of its users. This new design module and software release transforms FACTS to allow users to design an efficient adaptive platform trial. There are so many advantages of platform trials and now FACTS allows for thorough and efficient simulation for optimizing these trials.”
This initial platform trial module of FACTS 7 allows users to simulate trials where many treatments are tested, with treatments entering and leaving the trial over time. Its current simulation capabilities are for continuous and dichotomous endpoints with various trial level participant and arm constraints. In particular, users can specify a maximum enrollment time, number of participants, definition of successful treatments, participants per arm and concurrent treatments. In addition, it has the capability to simulate treatments arriving at different times during the trial and provide allocation options that include fixed proportion to control, allocation ratios dependent on the number of treatments and response adaptive randomization.
Tom Parke, Director of Software Solutions of Berry Consultants, added, "We are thrilled to be able to take some of the concepts and approaches of platform trials from the Berry Consultants scientific team and be able to apply that to our FACTS software. This new module brings some initial capabilities and features to our FACTS users as a first step, and we will be continuing to develop this platform trial software in future releases. We will continue to develop FACTS and provide to our users the latest and most innovative features in clinical trial design.”
With this release, FACTS continues to share a common structure, platform and philosophy: that simulation of clinical trials should be easy to set up, flexible, fast to run, and clear in their outcomes. FACTS allows users to specify trials across the whole spectrum from the simplest and widely used to the most innovative.
About Berry Consultants
Berry Consultants is a statistical consulting company specializing in innovative clinical trial design, analysis, execution, and software solutions for the pharmaceutical and medical device industry. We employ world-renowned experts in Bayesian statistics and strive to set the standard for adaptive clinical trial design and analysis across all medical disciplines. www.berryconsultants.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005122/en/
Contact information
Berry Consultants
(512) 213-6428
info@berryconsultants.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KCx Integrates Proprietary Data into FlexTrade’s AI Assistant, FlxAI12.5.2025 11:04:00 EEST | Press release
FlexTrade Systems, a global leader in multi-asset execution and order management systems, and Kepler Cheuvreux, a leading independent European financial services company through its KCx execution services, today announced the availability of KCx’s sophisticated analytical suite directly from FlexTrade’s AI assistant, FlxAI, to deliver intelligent, high-value insights into client workflows. With rapid advancements in AI, large language models are reshaping how financial firms interact with data. Trading desks are increasingly embracing conversational AI to streamline decision-making and extract actionable insights faster than ever before. In response to market drivers, the new workflow has been developed as part of a collaborative initiative between KCx’s and FlexTrade’s teams. Through the new collaboration, users of FlxAI, which is seamlessly embedded in FlexTrade's FlexONE OEMS and FlexTRADER EMS solutions, can actively query KCx liquidity drivers through natural language commands, su
Shin-Etsu Chemical Develops New Silicone Products for Personal Care Use That Will Improve Texture and Functionality in Cosmetics12.5.2025 09:30:00 EEST | Press release
Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) has developed new silicone products for personal care applications as part of its silicon chemistry-driven solutions (Shin-Etsu Silicones Solution-EngineeringTM). In the personal care industry, research and development activities are being carried out on various themes such as addressing diverse consumer demand and environmental issues and improving production efficiency. In response to these needs, Shin-Etsu Chemical has added new products to its lineup. [New Products] KF-6070W and KF-6080W are silicones in which some of the methyl groups in the molecular structure of dimethyl silicone oil (INCI name: dimethicone) have been replaced with hydrophilic functional groups. Both products combine high affinity with water due to their hydrophilic functional groups, while also imparting the excellent characteristics of silicone—high fluidity and smooth, non-sticky feel—to cosmetics
Cooler Master Launches Hyper 612 APEX: Compact, High-Performance CPU Cooler for Modern Builds12.5.2025 09:05:00 EEST | Press release
Cooler Master, a global leader in PC components and tech lifestyle solutions, today unveiled the Hyper 612 APEX, an all-new CPU air cooler engineered for users who demand cutting-edge thermal performance in a streamlined footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250511858017/en/ Cooler Master Hyper 612 APEX air cooler Featuring in-house developed superconductive composite heat pipes and the high-powered Mobius 120P fan, the Hyper 612 APEX delivers exceptional cooling efficiency while being 30% smaller than its predecessor, ensuring enhanced compatibility with large memory modules and tighter system builds. Ideal for gamers, content creators, and overclockers, the Hyper 612 APEX is meticulously designed to balance elite performance, user-friendly installation, and sleek aesthetics. “The Hyper 612 APEX is designed to meet the needs of users who want efficient cooling without the bulk,” said Jimmy Sha, Cooler Ma
Zeon and Sino Applied Technology Join Hands to Expand Single-Walled Carbon Nanotube Conductive Paste Product Line and Promote the Application of Next-Generation Lithium Batteries in Electric Vehicles12.5.2025 09:00:00 EEST | Press release
Zeon Corporation (Zeon) and Sino Applied Technology (SiAT) are thrilled to announce the signing of a strategic partnership in Taoyuan, Taiwan. As part of this collaboration, Zeon will lead a $20 million USD Series C fundraising round in SiAT to support the expansion of its production capacity for single-walled carbon nanotube (SWCNT) conductive paste, a critical nanomaterial for next-generation battery technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250511242604/en/ ZEONANO®, Single-Walled Carbon Nanotube produced by Zeon Super Growth Method The global demand for lithium-ion batteries is surging across consumer applications—such as electric vehicles, drones, and EVTOL aircraft—as well as industrial sectors, including AI server BBUs, renewable energy ESS, and automated robotics. This growth has intensified the need for SWCNTs, which can significantly enhance battery energy density and cycle life. Unlike tradition
New Study from UK’s Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care10.5.2025 13:45:00 EEST | Press release
As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK’s largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Prague, Czech Republic, the findings highlight the role of QbCheck, Qbtech’s remote testing solution, in enabling clinicians to make more confident, data-informed decisions, supporting a more personalized and collaborative care model. The tool allows for greater clarity when assessing symptoms and adjusting treatment plans over time, ensuring diagnostic accuracy and helping to improve alignment between clinicians and patients throughout the care journey. The results from ADHD 360’s implementation of this model showcase how a standardized approach to virtual ADHD care improves clinician confidence, reduces wait times, and enhances patient engageme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom